MOTS-c

Overview

MOTS-c (Mitochondrial Open-reading-frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It was identified in 2015 by Changhan Lee, Pinchas Cohen and colleagues at USC and is, alongside Humanin, one of the principal members of the mitochondrially-derived peptide (MDP) family.

MOTS-c is widely described as an endogenous exercise-mimetic. In skeletal muscle, treatment with MOTS-c activates the AMP-activated protein kinase (AMPK) pathway, increases GLUT4 translocation to the plasma membrane and enhances glucose uptake — a profile that overlaps with the metabolic adaptations produced by exercise. In rodent models, repeated administration improves insulin sensitivity, reduces diet-induced obesity and extends healthspan markers in aged animals.

An additional 2018 finding by Kim et al. demonstrated that MOTS-c can translocate to the nucleus under conditions of metabolic stress and bind regulatory regions of nuclear DNA, modulating expression of antioxidant-response and metabolic genes. This places MOTS-c in a small group of peptides with documented direct gene-regulatory activity, alongside the AEDG tetrapeptide.

This page summarises the published evidence on mechanism, animal and human research, safety profile and UK regulatory framing.

Mechanism of action

The most-characterised pathway is AMPK activation in skeletal muscle. MOTS-c increases the AMP:ATP ratio sensor activity, phosphorylates AMPK at Thr172, and engages the canonical downstream programme — increased fatty-acid oxidation, GLUT4 translocation, mitochondrial biogenesis through PGC-1α, and reduced lipogenesis. The net result resembles the metabolic adaptation produced by physical exercise.

A second mechanism involves the folate cycle. MOTS-c inhibits the folate-mediated one-carbon pathway at the level of AICAR accumulation, producing endogenous AICAR build-up. AICAR is itself a direct AMPK activator, providing a metabolic-intermediate pathway through which MOTS-c can amplify its primary signal.

The third mechanism — described by Kim and colleagues in 2018 — is direct nuclear gene regulation. Under conditions of metabolic stress, MOTS-c translocates from mitochondria to the nucleus, binds chromatin at antioxidant-response element (ARE) regions and modulates expression of genes including NRF2 targets. This implies a bidirectional mitonuclear communication system in which the mitochondrial genome encodes a peptide capable of directly regulating nuclear transcription.

Plasma MOTS-c levels decline with age in humans and are reduced in type 2 diabetes, paralleling Humanin. In a notable 2016 study by Lu and colleagues, plasma MOTS-c was inversely correlated with insulin resistance in a Chinese cohort, supporting its role as a circulating insulin-sensitising mitokine.

Research history

MOTS-c was reported in 2015 by Lee, Zhang and colleagues. The original paper demonstrated the peptide's existence, its origin in the mitochondrial 12S rRNA, and its principal metabolic effects in cell and mouse models. The 2018 Kim et al. paper extended the model to nuclear regulation, and a series of subsequent publications by the Cohen group at USC have explored exercise-MOTS-c interactions, ageing biomarkers and tissue-specific effects.

MOTS-c has been investigated in the context of postmenopausal bone loss, sarcopenia, hepatic steatosis and cardiac ischaemia-reperfusion injury, with broadly positive preclinical results across these models. Human translational work remains at an early stage, with published reports primarily comprising plasma-level correlation studies and small-scale pilot administration trials.

Summarised studies